IL-1β inhibitors, such as rilonacept and canakinumab, have shown promise in reducing lung cancer incidence and mortality, as well as in the treatment of autoinflammatory relapsing fever syndrome and Still’s disease (56). Here, IL1B is linked to lung cancer.